Antidepressants - Articles - Page 8

The Experience of Correctional Psychiatry

May 13, 2016

...

Psychopharmacology in Jails: An Introduction

May 13, 2016

Joe Simpson, PhD, MD

If you are interested in part-time correctional work, the best place to start is often the local jail—as opposed to a prison. What’s the difference between the two? A jail is a criminal justice facility operated by a city or county. It houses people who are awaiting trial or who...

CLINICAL UPDATE

Psychopharmacology in Jails: An Introduction

May 1, 2016

Joe Simpson, PhD, MD

Joe Simpson, PhD, MD. Supervising psychiatrist at the Los Angeles County DMH Jail Mental Health Services, CA Dr. Simpson has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There is a high demand for psychiatric care in U.S. correctional facilities. At any given time, about 1% of the adult population is incarcerated, and many of them have a psychiatric disorder of some sort.

The Experience of Correctional Psychiatry

May 1, 2016

Patrick Gariety, MD

Patrick Gariety, MD Psychiatrist at Group Health Behavioral Health Services, WA Dr. Gariety has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Patrick Gariety shares his experiences as a treatment clinician working in a facility with about 300 psychiatric patients, staffed with five psychiatrists and eight psychologists. The psychiatric population was extremely mixed, with most of the patients suffering from some form of chronic mental illness, and/or severe personality disorders.

Four Newer Antidepressants: Should You Use Them?

April 1, 2016

Steve Balt, MD and Talia Puzantian, PharmD, BCPP

Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb. Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.

Thinking Creatively About Treatment-Resistant Depression

April 1, 2016

J. Alexander Bodkin, MD

J. Alexander Bodkin, MD Director of the Clinical Psychopharmacology Research Program at McLean Hospital in Belmont, MA; assistant professor of psychiatry at Harvard Medical School Dr. Bodkin has disclosed that he has been a principal investigator in a study of brexpiprazole. Dr. Carlat has reviewed his interview and has found no evidence of bias in this educational activity.

Dr. Bodkin discusses methods for approaching treatment resistant depression and his perspective on depressive illness as a final common pathway for a number of different brain problems.

Antidepressant Use in Pregnancy and the Risk of Autism

February 1, 2016

Rates of autism diagnoses are on the rise. While no one knows for sure why, a new study explores whether the increased use of antidepressants during pregnancy might be one of the causes.

Antidepressants and Suicidal Ideation in Young People: A Practical Approach

November 1, 2015

Daniel Carlat, MD

In October of 2004, the FDA announced to drug companies that they should add black-box warnings about the risk of suicidal behavior in children and adolescents started on antidepressants. How have these black-box warnings affected clinical practice over the past decade?

Antidepressant Use in Children and Teenagers

November 1, 2015

This Expert Q&A covers key things that John Walkup, MD, looks for in child and adolescent patients with depression to determine how they are likely to respond to different kinds of medication.

Rexulti for Schizophrenia and MDD: Is It Abilify, Round 2?

September 1, 2015

On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).